Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.66 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.66 |
| ▸ | CCKBR | P32239 | 2/20 | 0.56 |
| ▸ | F2R | P25116 | 1/20 | 0.54 |
| ▸ | REN | P00797 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | PYGL | P06737 | 3/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28951561 | 1.00 | TAS1R3 (0.66) | TAS1R3TAS1R1CCKBRF2RREN | |
| SCHEMBL25517407 | 1.00 | TAS1R3 (0.66) | TAS1R3TAS1R1CCKBRF2RREN | |
| SCHEMBL30557031 | 0.95 | TAS1R3 (0.70) | TAS1R3TAS1R1CCKBRF2RCTSS | |
| SCHEMBL30174883 | 0.88 | CCKBR (0.61) | CCKBRF2RRENPYGLCYP51A1 | |
| SCHEMBL25517406 | 0.88 | CCKBR (0.61) | CCKBRF2RRENPYGLCYP51A1 | |
| SCHEMBL25194705 | 0.88 | CCKBR (0.61) | CCKBRF2RRENPYGLCYP51A1 | |
| SCHEMBL25224163 | 0.88 | CCKBR (0.61) | CCKBRF2RRENPYGLCYP51A1 | |
| SCHEMBL23711803 | 0.87 | CTSL (0.52) | TAS1R3TAS1R1F2R | |
| SCHEMBL28951200 | 0.87 | PYGL (0.65) | RENPYGLCYP51A1 | |
| SCHEMBL25517761 | 0.87 | PYGL (0.65) | RENPYGLCYP51A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | COCRYSTAL PHARMA, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-4132944-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | Cocrystal Pharma, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159453-A1 | INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION | VIM, ACE, ACE2 | TAS1R3 4078/4885TAS1R1 3310/4885CCKBR 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.